Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Disorders of the Neuromuscular Junction
- Case 31 Myasthenia Gravis with Acetylcholine Receptor Antibodies (AChR MG)
- Case 32 Myasthenia Gravis with Muscle-Specific Kinase Antibodies (MuSK MG)
- Case 33 Drug-Induced Myasthenia Gravis: Immune Checkpoint Inhibitor (ICI)-Related
- Case 34 Lambert–Eaton Myasthenic Syndrome (LEMS)
- Case 35 Congenital Myasthenic Syndromes (CMS): Dok7
- Myopathies
- Video legends
- Index
- References
Case 33 - Drug-Induced Myasthenia Gravis: Immune Checkpoint Inhibitor (ICI)-Related
from Disorders of the Neuromuscular Junction
Published online by Cambridge University Press: 29 November 2024
Book contents
- Neuromuscular Disease: A Case-Based Approach
- Neuromuscular Disease
- Copyright page
- Contents
- Contributors
- Foreword
- Preface to 2nd Edition
- Part I Evaluation and Treatment of Patients with a Neuromuscular Disorder
- Part II Neuromuscular Cases
- Disorders of the Anterior Horn Cell
- Peripheral Neuropathies
- Disorders of the Neuromuscular Junction
- Case 31 Myasthenia Gravis with Acetylcholine Receptor Antibodies (AChR MG)
- Case 32 Myasthenia Gravis with Muscle-Specific Kinase Antibodies (MuSK MG)
- Case 33 Drug-Induced Myasthenia Gravis: Immune Checkpoint Inhibitor (ICI)-Related
- Case 34 Lambert–Eaton Myasthenic Syndrome (LEMS)
- Case 35 Congenital Myasthenic Syndromes (CMS): Dok7
- Myopathies
- Video legends
- Index
- References
Summary
A 73-year-old man was referred by his oncologist because of dyspnoea occurring for one and a half weeks, and high CK levels (1341 U/L). For four years he was treated for a melanoma with pulmonary and cerebral metastases. Treatment included nivolumab that had been started three months previously. The dyspnoea was worse on exertion and when lying down. He also experienced some difficulties speaking clearly, and choking had occurred a few times during the past week. He had no diplopia. The complaints did not fluctuate. There was some recent myalgia, but he had not noticed any muscle weakness.
- Type
- Chapter
- Information
- Neuromuscular DiseaseA Case-Based Approach, pp. 163 - 164Publisher: Cambridge University PressPrint publication year: 2024
References
Suggested Reading
Astaras, C, de Micheli, R, Moura, B, Hundsberger, T, Hottinger, AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 2018;18(1):3. doi: 10.1007/s11910-018-0810-1. PMID: 29392441.CrossRefGoogle ScholarPubMed
Huang, YT, Chen, YP, Lin, WC, Su, WC, Sun, YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol 2020;11:634. doi: 10.3389/fneur.2020.00634. PMID: 32765397; PMCID: PMC7378376.CrossRefGoogle ScholarPubMed
Narayanaswami, P, Sanders, DB, Wolfe, G, et al. International consensus guidance for management of myasthenia gravis: 2020 Update. Neurology 2021;96(3):114–122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3. PMID: 33144515; PMCID: PMC7884987.CrossRefGoogle ScholarPubMed
Rossi, S, Gelsomino, F, Rinaldi, R, et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J Neurol 2023;270(6):2975–2986. doi: 10.1007/s00415-023-11625-1. Epub 2023 Feb 17. PMID: 36800019; PMCID: PMC10188572.CrossRefGoogle ScholarPubMed
Safa, H, Johnson, DH, Trinh, VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 2019;7(1):319. doi: 10.1186/s40425-019-0774-y. PMID: 31753014; PMCID: PMC6868691.CrossRefGoogle ScholarPubMed
Schneider, BJ, Naidoo J, Santomasso BD et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073–4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. PMID: 34724392.Google Scholar